Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.72 |
| ▸ | ITK | Q08881 | 11/20 | 0.72 |
| ▸ | BTK | Q06187 | 5/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.59 |
| ▸ | TEC | P42680 | 1/20 | 0.59 |
| ▸ | TXK | P42681 | 1/20 | 0.59 |
| ▸ | BMX | P51813 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | CD69 | Q07108 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14791244 | 1.00 | EGFR (0.72) | EGFRITKBTKJAK2LYN | |
| SCHEMBL18165644 | 0.95 | EGFR (0.77) | EGFRITKBTKJAK2LYN | |
| SCHEMBL21443568 | 0.89 | EGFR (0.80) | EGFRITKBTKJAK3 | |
| SCHEMBL17988449 | 0.88 | EGFR (0.74) | EGFRITKBTKJAK2LYN | |
| SCHEMBL13498103 | 0.88 | EGFR (0.74) | EGFRITKBTKJAK2LYN | |
| SCHEMBL13166543 | 0.88 | EGFR (0.75) | EGFRITKBTKJAK2LYN | |
| SCHEMBL12518316 | 0.87 | EGFR (0.73) | EGFRITKBTKJAK2LYN | |
| SCHEMBL14769280 | 0.85 | EGFR (0.81) | EGFRITKBTK | |
| SCHEMBL2353964 | 0.84 | EGFR (1.00) | EGFRITKBTKJAK3 | |
| SCHEMBL26158821 | 0.84 | EGFR (0.82) | EGFRITKBTKJAK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-9296737-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | EGFR 460/4885ITK 317/4885BTK 261/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.